Podcasts about Precision medicine

EPISODE DESCRIPTIONLisa Shufro is the storyteller's storyteller. A musician turned innovation strategist, TEDMed curator, and unapologetic truth-teller, Lisa doesn't just craft narratives—she engineers constellations out of chaos. We go way back to the early TEDMed days, where she taught doctors, scientists, and technocrats how not to bore an audience to death. In this episode, we talk about how storytelling in healthcare has been weaponized, misunderstood, misused, and still holds the power to change lives—if done right. Lisa challenges the idea that storytelling should be persuasive and instead argues it should be connective. We get into AI, the myth of objectivity, musical scars, Richard Simmons, the Vegas healthcare experiment, and the real reason your startup pitch is still trash. If you've ever been told to “just tell your story,” this episode is the permission slip to do it your way. With a bow, not a violin.RELATED LINKSLisa Shufro's WebsiteLinkedInSuper Curious ArchiveEight Principles for Storytelling in InnovationStoryCorps InterviewCoursera Instructor ProfileWhatMatters ProjectFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, email podcast@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Ever thought about why medications work differently for different people? In this episode of Absolute Gene-ius, we explore the exciting field of pharmacogenomics with Wendy Wang, pharmacogenetic laboratory supervisor at Children's Mercy Hospital in Kansas City. Wendy shares how genetics can influence drug metabolism, offering a glimpse into how precision medicine can revolutionize healthcare by tailoring treatments based on an individual's unique genetic makeup.At the heart of Wendy's research is CYP2D6, a cytochrome P450 enzyme responsible for metabolizing around 20% of all prescribed medications. She explains how her lab uses digital PCR to analyze copy number variations (CNV), offering a reliable and precise method to predict drug metabolism. Wendy dives into the complexities of structural variants, the role of digital PCR in enhancing assay efficiency, and why pharmacogenomics is a critical piece of the precision medicine puzzle. Her use of delightful metaphors—like comparing genetic testing to ladling soup—makes complex science both relatable and engaging.In the Career Corner, Wendy opens up about her winding path to molecular biology, which included studying classical antiquity and nearly pursuing a career in history. She emphasizes the importance of resilience in research, embracing failure as a learning opportunity, and encourages budding scientists to reach out to mentors and explore diverse interests. Plus, hear about her most embarrassing lab mishap (hint: it involves a fire alarm) and the proud moment of publishing her first, first-author paper.Visit the Absolute Gene-ius page to learn more about the guests, the hosts, and the Applied Biosystems QuantStudio Absolute Q Digital PCR System. 

What happens when you blend the soul of Mr. Rogers, the boldness of RuPaul, and just a pinch of Carrie Bradshaw? You get Sally Wolf.She's a Harvard and Stanford powerhouse who ditched corporate media to help people actually flourish at work and in life—because cancer kicked her ass and she kicked it back, with a pole dance routine on Netflix for good measure.In this episode, we unpack what it means to live (really live) with metastatic breast cancer. We talk about the toxic PR machine behind "pink ribbon" cancer, how the healthcare system gaslights survivors when treatment ends, and why spreadsheets and dance classes saved her sanity. Sally doesn't just survive. She rewrites the script, calls out the BS, and shows up in full color.If you've ever asked “Why me?”—or refused to—this one's for you.RELATED LINKS:Sally Wolf's WebsiteLinkedInInstagramCosmopolitan Essay: "What It's Like to Have the 'Good' Cancer"Oprah Daily Article: "Five Things I Wish Everyone Understood About My Metastatic Breast Cancer Diagnosis"Allure Photo ShootThe Story of Our Trauma PodcastFEEDBACK:Like this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, email podcast@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

This lecture is entitled Populations, Persons, and Precision Medicine: The Ethics of Emerging Information Technologies. It was presented by Paul Scherz of (then) the University of Virginia on March 22, 2024, at the University of Chicago.

AGNTCY - Unlock agents at scale with an open Internet of Agents. Visit https://agntcy.org/ and add your support.   What if AI could predict exactly when you'd get sick—and help you prevent it?   In this episode of Eye on AI, Dr. Eric Topol, world-renowned cardiologist, author, and AI health pioneer, joins us to unveil the future of preventive medicine. We dive deep into the themes of his new book Super Agers, which lays out a groundbreaking blueprint for extending healthspan—not just lifespan—through the power of multimodal AI and deep biological data.   Dr. Topol explains how AI models can now analyze a full-stack of human data—genomics, proteomics, metabolomics, microbiome, and more—to forecast age-related diseases like cancer, Alzheimer's, and heart disease decades before symptoms appear. This isn't science fiction. It's here now.   If you're interested in the intersection of AI, longevity, and the future of medicine, this is a must-listen.   Where AI Works tackles the big questions shaping AI's role in business today, cutting through the hype to deliver actionable insights for leaders. Brought to you by the Wharton School, in collaboration with Accenture, this podcast combines cutting-edge research with real-world case studies to uncover how top companies are using AI to upskill workforces, enhance customer experiences, boost productivity, and streamline operations.  Check it out:  https://link.cohostpodcasting.com/f5e223b4-da0c-4fc8-bbf3-5f24c15f8fd2?d=sxo9xhJN2    Stay Updated: Craig Smith on X:https://x.com/craigss Eye on A.I. on X: https://x.com/EyeOn_AI (00:00) The Power of Precision Medical Forecasting (01:53) Eric Topol's Journey into Digital & AI Medicine (03:27) Using AI to Prevent Aging-Related Diseases (05:25) The Challenge of Health Data Privacy & Ownership (09:05) Genetic Risk to Deep Data Insights (11:20) Personalized Prevention Through Lifestyle & Biomarkers (13:59) Why Anti-Aging Drugs Are Still Years Away (16:18) What are Organ Clocks (19:34) The Longevity Industry's Flawed Use of AI (21:59) Top AI Pioneers Endorse “Super Agers” (24:21) Which Longevity Startups Are Getting It Right? (26:27) Why Topol Refuses to Join Longevity Startups (28:57) Topol's Own Health Data & Lessons Learned (30:25) How Accurate Is AI at Predicting Disease Timing? (31:47) The Truth About Genetic Risk and Cancer Detection (33:33) AI-Driven Cancer Detection: A Smarter Approach (38:51) How Precision Medicine Has Evolved (41:02) The Risky Reality of Anti-Aging Interventions (44:39) Why Healthspan Matters More Than Lifespan

Susan Athey, PhD, of Standford University joins JAMA+ AI Editor in Chief Roy H. Perlis, MD, MSc, to discuss her research on machine learning to target behavioral nudges for college students and their potential implications for health care. Related Content: How an Economist's Application of Machine Learning to Target Nudges Applies to Precision Medicine

 Most cancer drugs fail. Not because the science is wrong—because we're solving the wrong problems.The cost? Over $2 billion per failure. And for the patient waiting on a miracle—there's no second chance.Behind the headlines of “precision medicine,” there's a deeper story nobody's telling. Until now. 

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/ZKX865. CME/MOC/CPE/AAPA/IPCE credit will be available until May 1, 2026.Taking a Step Forward in HCM Precision Medicine: Aligning Clinical and Managed Care Approaches With New Guidelines, Long-Term Evidence, and Real-World Experience In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through an educational grant from Bristol Myers Squibb.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/ZKX865. CME/MOC/CPE/AAPA/IPCE credit will be available until May 1, 2026.Taking a Step Forward in HCM Precision Medicine: Aligning Clinical and Managed Care Approaches With New Guidelines, Long-Term Evidence, and Real-World Experience In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through an educational grant from Bristol Myers Squibb.Disclosure information is available at the beginning of the video presentation.

View the Show Notes For This Episode Dr. Kristine Burke discusses the Prevention and Reversal of Neurological Conditions with Dr. Ben Weitz. [If you enjoy this podcast, please give us a rating and review on Apple Podcasts, so more people will find The Rational Wellness Podcast. Also check out the video version on my WeitzChiro YouTube page.]   Podcast Highlights       ________________________________________________________________________________________________________ Dr. Kristine Burke is a triple board-certified Precision Medicine Physician, Author, Educator, and Researcher.  She is an expert on the prevention and reversal of chronic diseases such as dementia, diabetes, and heart disease. She is the Chief Medical Director and the CEO of Precision Medicine in Northern California. Her website is Truehealthcpm.com. Dr. Ben Weitz is available for Functional Nutrition consultations specializing in Functional Gastrointestinal Disorders like IBS/SIBO and Reflux and also Cardiometabolic Risk Factors like elevated lipids, high blood sugar, and high blood pressure.  Dr. Weitz has also successfully helped many patients with managing their weight and improving their athletic performance, as well as sports chiropractic work by calling his Santa Monica office 310-395-3111.

There's a care model for schizophrenia that actually works—why isn't it everywhere? On this episode, W. Gordon Frankle, MD, MBA, Vice Chair of Psychiatry at NYU Langone Health, shares how his team in Brooklyn is building a new model for treating serious mental illness—one rooted in long-term, relationship-driven, team-based care. From wraparound services to precision psychiatry, this conversation explores what happens when you bring humanity, structure, and innovation to a population too often left behind.Also discussed:The first novel schizophrenia drug in over 50 years (Cobenfy)Why clozapine is underused—and how that may finally changeThe potential of brain imaging and biomarkers in psychiatric treatmentWhat a real community mental health system looks likeWhy trust, not just treatment, is essential for recovery

In this episode, we delve into our latest biohacking experiments and share insights from recent interviews with leading experts in the health and wellness space. We discuss the concept of "bioharmonizing" with Dr. Melissa Sonners, a functional medicine approach to thyroid conditions like Hashimoto's with Dr. Heather Stone, PEMF technology with Mike & Alyssa from Align Mat, the role of genomics in precision medicine with Dr. Matt Dawson from Wild Health, and the emotional aspects of fertility with Beth Gulotta from Quiet the Clock. Join us for this fun and inspiring conversation!SHOW NOTES:0:39 Welcome to the show!2:57 Renee's current sleep experiment8:59 Cell detox & parasite cleansing12:02 Most recent podcast recap12:57 Ep 289: Dr Melissa Sonners14:21 Getting over people-pleasing16:59 Ep 290: Dr Heather Stone18:03 Gaslighting from doctors20:40 Missing nutrition link for Hashimoto's22:56 Ep 291: Mike & Alyssa of Align Mat24:25 All the PEMF mats we've tried28:10 *PIQUE TEA*30:21 *ALIGN MAT*31:58 Ep 292: Wild Health34:32 Are higher fat diets for you?37:14 Ep 293: Beth Gulotta40:31 Importance of getting into parasympathetic42:23 Noticing the ‘Red Ferrari'43:47 Upcoming EventsRESOURCES:Onera At-Home Sleep StudyALIGN MAT - Save $250 with code: BIOHACKERBABESPIQUE TEABe Inspired Mama - Dr. Melissa SonnersWild HealthQuiet the Clock - Beth GulottaUltimate Wellness in Miami - Save with code: BIOHACKERBABESHealthspan SummitHack Your Health in Tampa - Save with code: BIOHACKERBABESOur Sponsors:* Check out Puori: https://Puori.com/BIOHACKERBABESSupport this podcast at — https://redcircle.com/biohacker-babes-podcast/donationsAdvertising Inquiries: https://redcircle.com/brands

Dr. Florence Comite, MD is a clinician-scientist, endocrinologist, and the leading expert in the fields of healthy longevity and precision medicine. Her international reputation stems from her innovative approach to leveraging proprietary clinical and wearable data in her private clinical and virtual practice to detect, predict, and reverse biological aging, while optimizing health and vitality.   As a graduate of Yale School of Medicine, Dr. Comite served as a faculty member for twenty-five years with a distinguished triple appointment in Endocrinology (Internal Medicine and Pediatrics) and Reproductive Endocrinology (Gynecology and Andrology). During her career, she trained at the National Institutes of Health and founded Women's Health at Yale, establishing the nation's first women-only clinic.   In 2005, Dr. Comite founded the Comite Center for Precision Medicine & Healthy Longevity in New York City, where she developed the groundbreaking Nof1™ clinical process, treating each patient as a single subject clinical trial. The Center's success has led to expansions in Palo Alto and Miami Beach. Her innovative approach has attracted a global clientele, including forward-thinking physicians, industry leaders, and entrepreneurs, each receiving personalized healthcare interventions tailored to their individual needs. Her commitment to advancing medical science is evident through her extensive research and publications in prestigious journals such as the New England Journal of Medicine, JAMA: The Journal of the American Medical Association, and the Journal of the Endocrine Society. Dr. Comite's pioneering research spans across children, women, and men, recognizing the critical role of the entire system in aging and disease.   In 2013, she authored the bestselling book "Keep It Up: The Power of Precision Medicine to Conquer Low T and Revitalize Your Life," focusing on androgen deficiency and vitality in aging men. Her next book, "Invincible: Eliminate the Disorders of Aging for a Healthy, Long Life," will be published by Little Brown, Spark in Spring 2026. Through her startup Groq Health, Dr. Comite is scaling her precise methodology of precision medicine to a digital clinic delivered virtually.   As a sought-after keynote speaker, Dr. Comite continues to captivate audiences worldwide, sharing her expertise and vision for the future of precision medicine and healthy longevity.

This Saturday on The Heart of Innovation, Emmy Award-winning Journalist Kym McNicholas and Interventional Cardiologist Dr. John Phillips welcome James Maskell to discuss TruNeura, founded by Dr. Kristine Burke, to pioneer personalized medicine for Alzheimer's and dementia. Inspired by innovative treatments that helped his own father, Maskell will share how TruNeura's precision medicine approach is creating new possibilities for patients with cognitive decline. The conversation will explore how vascular health impacts brain function, with special attention to how arterial buildup restricts critical blood flow to the brain. Get an exclusive preview of the upcoming Alzheimer's Summit starting Tuesday, where experts will gather to discuss the latest advances in cognitive health. While challenging, these new approaches offer hope for many families. Join us for this important conversation and visit truneura.com to learn more about the company and drtalks.com/summit/alzheimers for summit information. #AlzheimersResearch #PrecisionMedicine #CognitiveHealth #peripheralarterydisease #padsupport #globalpadassociation #theheartofinnovation

The following article of the Health industry is: “Opportunities, Challenges of Diagnostic Precision Medicine” by Jorge Melendez Zajgla, General Director, Instituto Nacional de Medicina Genomica.

In this episode of the Scope of Things, host Deborah Borfitz brings you the news on a precision medicine initiative in Sweden integrating research with healthcare, newly available cardiometabolic clinical data registries for real world evidence projects, updates to guidelines on the reporting of clinical trials, AI improving the monitoring of movement disorders, and the best-yet biomarker for stroke and dementia risk. Joining the conversation is Briony Swire-Thompson, director of the Psychology of Misinformation Lab at Northeastern University Network Science Institute, to discuss the current misinformation epidemic and how clinical trials and sites can best deal with it. News Roundup   Precision Omics Initiative Sweden (PROMISE) Correspondence in Nature Medicine  Article in Clinical Research News  Cardiometabolic clinical data registries Article in Clinical Research News New CONSORT reporting guidelines  Article in JAMA VisionMD for analyzing motor function Article in Nature Best-yet biomarker for stroke and dementia risk Article in Diagnostics World News  The Scope of Things podcast explores clinical research and its possibilities, promise, and pitfalls. Clinical Research News senior writer, Deborah Borfitz, welcomes guests who are visionaries closest to the topics, but who can still see past their piece of the puzzle. Focusing on game-changing trends and out-of-the-box operational approaches in the clinical research field, the Scope of Things podcast is your no-nonsense, insider's look at clinical research today.

In this three-part series, Jonathan Sackier speaks with Peder Langeland Myhre about cutting-edge advancements in heart failure research, the importance of biomarker-driven care, the challenges of implementing digital health tools globally, and how Norway is reshaping participation in cardiology clinical trials. Timestamps:  02:06 – Skiing & heart  04:02 – Blix award impact  07:51 – Heart failure biomarkers 

In this three-part series, Jonathan Sackier speaks with Peder Langeland Myhre about cutting-edge advancements in heart failure research, the importance of biomarker-driven care, the challenges of implementing digital health tools globally, and how Norway is reshaping participation in cardiology clinical trials. Timestamps:    00:21 – Biomarker disparities  04:52 – Norway trial challenges  07:15 – Boosting trial engagement 

In this three-part series, Jonathan Sackier speaks with Peder Langeland Myhre about cutting-edge advancements in heart failure research, the importance of biomarker-driven care, the challenges of implementing digital health tools globally, and how Norway is reshaping participation in cardiology clinical trials.  Timestamps:    00:17 – Digital health equity  06:00 – Podcasts in medicine  07:59 – Three cardiology wishes 

⏰

In this episode, we sit down with Dr. Matthew Dawson, the founder and CEO of Wild Health, and leader in genomics-based precision medicine. Dr. Matt breaks down what precision medicine truly means--how it goes beyond traditional healthcare to create highly personalized plans based on your unique genetic blueprint and blood work. We explore some of the most important genes to assess for optimizing health, performance, and longevity, including the ApoE gene. He shares powerful insights into the future of medicine and why understanding your genetics is crucial for extending healthspan. Plus, we open up about our own personal Wild Health test results and how they've shaped our individual wellness journey. This conversation is packed with actionable insights you won't want to miss!Dr. Matthew Dawson is the founder and CEO of Wild Health, a genomics-based precision medicine company, and the CEO of TruDiagnostic, an epigenetics testing lab. He has authored two textbooks, published over two dozen studies, lectured in over 20 countries, and won national awards for education and innovation. His passion is unlocking the secrets of the genome and epigenome and using them to optimize health and maximize healthspan. He lives in the woods with his wife, four children, and two dogs.SHOW NOTES: 0:31 Welcome to the show!3:57 Dr. Matt Dawson's Bio4:40 Welcome Dr. Matt to the show!5:14 What is “Precision Medicine”?7:14 Your genes are not your destiny11:09 Renee's experience with Bulletproof coffee11:38 MTHFR & Homocysteine12:43 Combining lab work with genetics17:24 Alzheimer's genetics20:32 What to do for APOE-3/422:56 Biomarkers for optimal health 24:28 Can you change your sleep chronotype?28:26 Genes for telomere length31:37 *ALIGN MAT*33:16 *PIQUE TEA*35:27 Boosting BDNF37:30 Something new about HbA1C!39:47 FOXO3 Gene for Longevity43:40 Blue Zones & social connection45:12 Testing Biological Age49:08 Caloric Restriction for Longevity51:42 The perfect diet for your genes53:25 Comparing macro tolerances57:37 Wild Health reports 59:12 Coming soon for Precision Medicine!1:04:16 His final piece of advice1:04:56 Thanks for tuning in!RESOURCES:Website: wildhealth.com - discount code: BIOHACKERBABESInstagram: wildhealthmdLinkedIn: Wild HealthMy Align Mat - discount code: BIOHACKERBABES to save $250Pique Tea - Save $ with this link!Puori - Save 20% with discount code: BIOHACKERBABESEffecty - Save $50 with discount code: BIOHACKERBABESOur Sponsors:* Check out Effecty and use my code BIOHACKERBABES for a great deal: https://www.effecty.com* Check out Puori: https://Puori.com/BIOHACKERBABESSupport this podcast at — https://redcircle.com/biohacker-babes-podcast/donationsAdvertising Inquiries: https://redcircle.com/brands

This week, we interview Dr. Cristofanilli, a globally recognised expert in inflammatory breast cancer research and precision medicine. With decades of clinical experience and groundbreaking contributions to translational research, he has transformed the way we approach metastatic breast cancer, leading advances in liquid biopsy, molecular profiling, and targeted therapies.Dr Cristofanilli serves as the Director of Breast Medical Oncology, Associated Director of Precision Oncology at the Meyer Cancer Centre, and co-leader of the MCC Breast Cancer Disease Management team, in addition to being the Scientific Director of the Englander Institute of Precision Medicine.For more episodes, resources and blog posts, visit www.inquisitiveonc.comPlease find us on Twitter @InquisitiveOnc!If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.comArt courtesy of Taryn SilverMusic courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.Oncology for the Inquisitive Mind is recorded with the support of education grants from our foundation partners Pfizer, Gilead Pharmaceuticals and Merck Pharmaceuticals. Our partners have access to the episode at the same time you do and have no editorial control over the content. Hosted on Acast. See acast.com/privacy for more information.

In this compilation episode of the Tech Leaders Playbook, we bring you a powerhouse mix of insights from top minds exploring how AI is transforming marketing, personal branding, and precision healthcare. You'll hear expert insights on why emotional intelligence is the new edge in the age of automation, how personal connection and consistent content win over sterile AI-generated noise, and what it means to position your startup like a media company. We also dive into the future of healthcare—where biomarker-driven AI can detect risks before they escalate—and the ethical, societal, and regulatory challenges we must navigate as AI and robotics become more integrated in our daily lives. Packed with practical advice and future-forward thinking, this episode is a must-listen for any tech-savvy leader.TakeawaysAI has redefined marketing strategies for businesses of all sizes.Emotional intelligence is crucial in maintaining authenticity in branding.Building a personal brand requires consistent effort and community engagement.Communication with consumers in real-time is essential for brand success.Content creation should focus on providing value rather than just selling.Positioning a startup as a media company can enhance its market presence.Transparency and direct communication with consumers build trust.Generosity in sharing knowledge can significantly boost personal branding.The digital marketplace is noisy, making it harder to stand out.AI in healthcare faces regulatory challenges related to data privacy.Transformative AI can significantly impact drug discovery processes.Predictive models can help assess patient risks effectively.Timely interventions are crucial for improving patient outcomes.Precision medicine focuses on delivering care at the right time.Ethical considerations in AI development are still evolving.Robotics can play a role in enhancing safety in schools.General intelligence could revolutionize how robots interact with humans.AGI can facilitate knowledge transfer between robots.Adapting robots to changing environments is essential for their effectiveness.Chapters00:00 The Rise of AI in Marketing02:46 Balancing AI and Human Touch06:05 Building Personal Brands in the Digital Age08:51 The Importance of Community and Feedback11:54 Content Creation as a Long-Term Strategy15:11 Precision Medicine and AI Innovations17:52 Challenges of AI in Healthcare26:35 Navigating AI Regulations in Healthcare28:01 Transformative AI in Drug Discovery30:54 Predicting Patient Risks with AI34:19 Precision Medicine and Timely Interventions36:45 Ethical Considerations in AI Development39:32 The Future of Robotics and AI in Society43:50 General Intelligence and Autonomous Systems49:30 Breakthroughs in AGI and Home Robotics

In Episode 66 of the Precision Medicine Podcast, host Karan Cushman kicks off a vital new series, Bringing Precision Medicine to Every Patient, in collaboration with Dr. Kashyap Patel, a nationally respected community oncologist and founder of the No One Left Alone initiative. This series explores what it takes to close the gap between innovation and access in precision cancer care—especially in community and rural settings where disparities remain greatest. Dr. Patel, a long-time advocate for equitable oncology care, shares the real-world barriers patients face—from gaps in provider awareness to financial constraints and restrictive payer policies—and how his organization is actively working to address them. He also offers powerful patient stories that highlight the life-saving potential of timely biomarker testing and personalized therapies.Joining the conversation is Dr. Angella Charnot-Katsikas, a molecular pathologist, policy leader at Palmetto GBA, and breast cancer survivor, who brings a unique perspective from both the clinical and payer sides. She emphasizes the importance of collaboration across care teams, the need for rapid diagnostic turnaround, and the urgency of keeping pace with evolving clinical guidelines.Together, the guests affirm that precision medicine is the standard of care—but for too many, it's still not the reality. This episode lays the foundation for a transformative series focused on dismantling systemic barriers and ensuring every patient—regardless of their zip code—can benefit from the best of modern cancer care.

Ochre Bio co-founder and CSO Quin Wills spoke with In Vivo about the UK-based company's novel approach to finding and validating RNA therapies for chronic liver diseases.

This is the latest episode of the free DDW narrated podcast, titled “Innovation enabled by new drug discovery technologies”, which covers two articles written for DDW Volume 24 – Issue 3, Summer 2023. They are called: “Accelerating biotherapy and personalised medicine with long DNA” and “The microbiome in precision medicine”. In the first article, Matt Hill, Founder and CEO of Elegen writes about the importance of innovation in DNA synthesis to address critical bottlenecks in biotherapy development. In the second article, Katie Gillette, Senior Project Leader, Eliza French, Analyst, and Graham Friedman, Analyst, DeciBio, provide an industry overview of the role of the microbiome in precision medicine, and its interplay with research tools, diagnostics, and therapeutic development.

In this episode, host Jonathan Sackier speaks with Alexander Spira about cutting-edge advances in lung and colorectal cancer, including EGFR and KRAS-targeted therapies. They also discuss Spira's leadership in oncology research, his thoughts on the evolving ‘town-gown' dynamic in US medicine, and his hopes for the future of cancer care.  Timestamps:  00:00 – Introduction 01:50 – Most memorable family travel adventure 03:30 – What inspired you to go into oncology 05:49 – Three recent publications in lung cancer 07:02 – Real-world data on colorectal cancer 08:15 – Sex/gender differences in non-small cell lung cancer 11:53 – The science of KRAS mutations and drug development 15:07 – Accelerating diagnostics and access to therapies 17:13 – The ‘town-gown' debate in American healthcare 18:09- Three Wishes 

Not all salts are created equal!

The future of healthcare is personalized, data-driven and powered by AI, but what does that really mean for patients and providers? We connected with Dr. Jared Pelo, Co-Founder and Chief Medical Officer at Bionic Health to explore how precision medicine is transforming preventive care and the doctor-patient relationship. Dr. Pelo discusses: From one-size-fits-all to precision medicine Personalized, predictive and proactive care models The power of AI, wearables and real-time health data Empowering patients and clinicians for better care Find Dr. Pelo's work at https://www.bionichealth.com Subscribe and stay at the forefront of the digital healthcare revolution. Watch the full video on YouTube @TheDigitalHealthcareExperience The Digital Healthcare Experience is a hub to connect healthcare leaders and tech enthusiasts. Powered by Taylor Healthcare, this podcast is your gateway to the latest trends and breakthroughs in digital health. Learn more at taylor.com/digital-healthcare About Us: Taylor Healthcare empowers healthcare organizations to thrive in the digital world. Our technology streamlines critical workflows such as procedural & surgical informed consent with patented mobile signature capture, ransomware downtime mitigation, contactless patient check-in and more. Learn more at taylor.com/healthcare/imedhealth   The Digital Healthcare Experience Podcast: Powered by Taylor Healthcare Produced by Naomi Schwimmer  Hosted by Chris Civitarese Edited by Eli Banks Music by Nicholas Bach  

This week, Jonathan is joined by Shaji Kumar, an expert in hematology and oncology, particularly multiple myeloma, who has made significant contributions to both clinical and translational science. Timestamps:  (00:00) – Introduction   (02:23) – Drug combinations and myeloma biology  (08:34) – Treating newly diagnosed multiple myeloma  (17:24) – Quadruplet regimens   (23:09) – Clinical trials for plasma cell malignancies  (28:04) – The bone marrow microenvironment in multiple myeloma  (30:29) – “Blind men and an elephant”  (33:58) – Kumar's three wishes for healthcare   

A cutting-edge technology and an exciting recent hire hint at exciting developments in the future of precision medicine in the diagnosis and treatment of Alzheimer's disease.

Dr. Scott Younger is the Director of Disease Gene Engineering within the Genomic Medicine Center at Children's Mercy Hospital. His research focuses on producing patient-derived cellular models to develop functional precision medicine. He talks about using personalized antisense oligonucleotides to reverse disease phenotypes in organoid models of Duchenne muscular dystrophy. He also discusses his lab's personal connections to the rare disease community and the opportunities for collaborations with clinicians at Children's Mercy.

Physician Tina Stankovic is an ear, nose, and throat specialist and a lover of music whose seemingly disparate pursuits — medicine and music — have led her to a groundbreaking career in hearing research. She recently worked with music legend Paul Simon during his well-publicized battle with hearing loss and he has become a vocal advocate for hearing research. New understandings and new approaches like regenerative medicine have put the once-impossible dream of hearing restoration within reach, Stankovic tells host Russ Altman on this episode of Stanford Engineering's The Future of Everything podcast.Have a question for Russ? Send it our way in writing or via voice memo, and it might be featured on an upcoming episode. Please introduce yourself, let us know where you're listening from, and share your question. You can send questions to thefutureofeverything@stanford.edu.Episode Reference Links:Stanford Profile: Konstantina M. StankovicStanford Researchers Assist Paul Simon with his Return to the StageInside the Stanford Initiative to Cure Hearing Loss: Cutting-Edge Science and InnovationConnect With Us:Episode Transcripts >>> The Future of Everything WebsiteConnect with Russ >>> Threads / Bluesky / MastodonConnect with School of Engineering >>> Twitter/X / Instagram / LinkedIn / FacebookChapters:(00:00:00) IntroductionRuss Altman introduces guest Tina Stankovic, a professor of otolaryngology and neurosurgery at Stanford University.(00:03:36) Why Hearing LossWhat inspired Tina's lifelong journey into hearing science.(00:04:17) Treating Hearing LossLimits of current options and lack of FDA-approved therapies.(00:05:23) Causes of Hearing LossThe two main categories of hearing loss: conductive vs. sensorineural.(00:07:47) Inside the Inner EarThe complexity of the inner ear, and why diagnosis is so difficult.(00:09:22) Tinnitus & Hearing LossWhy ear damage can cause phantom sounds in the brain.(00:10:28) Emerging Technologies in Hearing ResearchNew technologies that are evolving treatment approaches.(00:15:19) Recreating the Ear in the LabChallenges the inner ear's unique composition pose to researchers.(00:20:02) AI Applications in Hearing DiagnosisThe ways AI is transforming diagnosis and genetic analysis.(00:21:31) Can Ears Regrow?Why humans don't regenerate ear cells—but mice might help.(00:23:55) Emotional & Social Toll of Hearing LossHow hearing loss can lead to isolation, stigma, and cognitive decline.(00:26:06) Born Deaf vs. Later Hearing LossExperiential differences between those with early and late hearing loss.(00:27:52) Paul Simon's Role and AdvocacyHow the artist got involved with Tina's work and the initiative at Stanford.(00:29:44) Protecting Your HearingBest practices for protecting your hearing.(00:33:21) Conclusion Connect With Us:Episode Transcripts >>> The Future of Everything WebsiteConnect with Russ >>> Threads / Bluesky / MastodonConnect with School of Engineering >>>Twitter/X / Instagram / LinkedIn / Facebook

In this episode of the EMJ Podcast, Jonathan Sackier sits down with Faranak Kamangar, Chair of Dermatology at Palo Alto Medical Foundation and President of the San Francisco Dermatological Society, to discuss the future of AI and telehealth in dermatology.    Timestamps:  00:00 – Introduction  01:41 – DermGPT: bringing AI to dermatology  07:35 – Why telehealth is here to stay  11:15 – Targeted immunotherapies: what's new?  16:57 – Using media to drive education  22:39 – Precision medicine in melanoma  27:15 – Kamangar's podcast ‘The Future of Dermatology'  31:05 – Three wishes for healthcare  

Welcome to Research Renaissance, presented by the Karen Toffler Charitable Trust. In this episode, host Deborah Westphal sits down with Dr. Kasper Roet, CEO and co-founder of QurAlis, to explore the evolution of ALS drug development, the power of genetic insights, and the future of personalized medicine for neurodegenerative diseases.

Want to break into pharmacogenomics and precision medicine? In this episode, I sit down with Dr. Josiah Allen, a precision medicine pharmacist with nearly 20 years of experience in genomics, psychiatry, and clinical research. We explore how pharmacogenomics is revolutionizing patient care, prescribing, and the role of pharmacists in the future of medicine. We cover: • How Josiah transitioned from industry to clinical practice in pharmacogenomics • The multidisciplinary approach to precision medicine at St. Elizabeth Healthcare • Why pharmacists are the ideal leaders in pharmacogenomics • The future of personalized medicine and emerging fields beyond PGx • How to successfully implement pharmacogenomics in a healthcare setting • The importance of patient empowerment, education, and shared decision-making If you're a pharmacist looking to future-proof your career and expand into precision medicine, this episode is a must-listen! Join the ElevateRx Pharmacogenomics Summit to learn how to bring Pharmacogenomics to your practice - https://elevaterx.live/ Follow Dr Josiah Allen [https://www.linkedin.com/in/allenjosiah] on LinkedIn About me:

In today's episode, you will learn a series of vocabulary words that are connected to a specific topic. This lesson will help you improve your ability to speak English fluently about a specific topic. It will also help you feel more confident in your English abilities.5 Vocabulary WordsTelemedicine: (noun) The remote delivery of healthcare services, such as diagnosis, consultation, and treatment.Example sentences: Telemedicine has become increasingly popular in recent years.Telemedicine appointments can be more convenient for patients.Telemedicine can help to reduce healthcare costs.Genetic Engineering: (noun) The deliberate modification of an organism's genome using genetic engineering techniques.Example sentences: Genetic engineering can be used to treat genetic diseases.Genetic engineering raises ethical concerns about the manipulation of life.Genetic engineering has the potential to improve crop yields and resistance to pests.Telehealth: (noun) The use of digital information and communication technologies to provide health care services.Example sentences: Telehealth can improve access to healthcare, especially in rural areas.Telehealth appointments can be more convenient and cost-effective for patients.Telehealth can be used for a variety of healthcare services, including mental health counseling and chronic disease management.Remote Patient Monitoring: (noun) The use of technology to monitor a patient's health status from a distance.Example sentences: Remote patient monitoring can help to prevent hospitalizations.Remote patient monitoring devices can track vital signs and other health metrics.Remote patient monitoring can improve patient outcomes and reduce healthcare costs.Precision Medicine: (noun) A form of medicine that uses information about a patient's genes, proteins, and environment to prevent, diagnose, and treat disease.Example sentences: Precision medicine can lead to more effective and personalized treatments.Precision medicine requires advanced genetic testing and analysis.Precision medicine has the potential to revolutionize healthcare.A Paragraph using the 5 vocabulary wordsHealth tech is revolutionizing the way we approach healthcare. Telemedicine and remote patient monitoring allow for convenient and accessible healthcare, especially for those in remote areas. Genetic engineering and precision medicine are transforming treatments by tailoring therapies to individual patients' genetic makeup. These advancements, coupled with the power of artificial intelligence, are enabling earlier disease detection and more effective treatments. As telehealth continues to gain popularity, the future of healthcare holds immense promise for improving patient outcomes and enhancing overall well-being.If you want to sign up for the free daily English vocabulary newsletter, go towww.dailyenglishvocabulary.com

This episode of the Wild Health podcast dives deep into the power of Precision Medicine in crafting personalized nutrition plans. Hosts Dr. Erin Faules and Ariana Fiorita, an expert dietitian and health coach, explore how genetics, blood work, and real-time data can transform the way we approach food. From Continuous Glucose Monitoring (CGM) to genetic insights on macronutrient processing, they discuss how personalized health strategies can optimize energy levels, metabolic function, and long-term well-being. They also highlight the invaluable role of health coaches in helping patients bridge the gap between data and daily action, ensuring that lifestyle changes are both effective and sustainable. If you've ever wondered why one-size-fits-all diets don't work—or how to truly personalize your nutrition—this episode is a must-listen!

In this episode of Absolute Gene-ius, Dr. C. Dustin Rubinstein takes us inside the world of advanced genome editing, where cutting-edge tools like CRISPR and digital PCR are helping shape the future of biomedical research.As the Director of the Advanced Genome Editing Laboratory at the University of Wisconsin-Madison, Dr. Rubinstein shares how his lab develops genetically engineered pig models to study diseases like neurofibromatosis and cancer, providing researchers with more clinically relevant models than traditional small animals. He explains how digital PCR plays a crucial role in confirming genome edits with absolute precision, eliminating the ambiguity that often comes with qPCR and sequencing alone. The discussion dives into the advantages of dPCR for copy number variation analysis and gene editing confirmation, emphasizing the importance of multiple complementary technologies in modern molecular biology.Beyond the science, Dr. Rubinstein reflects on his career path, the value of mentors, and the unpredictable nature of scientific discovery. He also joins in on some lighthearted lab humor and shares his most embarrassing (and proudest) moments in research. Tune in for an insightful and entertaining look at the intersection of gene editing, career evolution, and the future of molecular biology.Visit the Absolute Gene-ius pageto learn more about the guests, the hosts, and the Applied Biosystems QuantStudio Absolute Q Digital PCR System. 

Segments 1 and 2: Ilyce Glink, owner of Think Glink Media and Best Money Moves, joins WGN’s John Williams to give updates on the markets along with the economic damage coming from shifts in US policy. Ilyce also warns listeners about identity theft scams and what to do if you encounter them. Segment 3: Jim Dallke, Director […]

My guest Brian Pla’s journey from the finance sector to the forefront of regenerative medicine and biocosmetics illustrates his adept transition and entrepreneurial spirit. Initially making his mark in finance and co-founding a foreign currency trading firm, Pla’s subsequent venture into the medical field was sparked by his personal experience with cell-based therapies. This shift led him to introduce new approaches in precision medicine and cell-based treatments, contributing to advancements in non-invasive and minimally invasive procedures. In 2017, he founded Gentera Centers for Precision Medicine and Plastic Surgery, focusing on personalized care and precision medicine, guiding Gentera to become a recognized name in regenerative medicine. The company's innovative approach sets a new standard for rejuvenation by utilizing exosomes—tiny, naturally occurring messengers in the body that promote your appearance at the cellular level. This advanced science is redefining what’s possible in non-invasive treatments, offering solutions that improve skin elasticity, reduce fine lines, enhance radiance, and revitalize thinning hair. Full show notes: https://bengreenfieldlife.com/exosomepodcast Episode Sponsors: Ketone-IQ: Ketones are a uniquely powerful macronutrient that can cross the blood-brain barrier and increase brain energy and efficiency. With a daily dose of Ketone-IQ, you'll notice a radical boost in focus, endurance, and performance. Save 30% off your first subscription order of Ketone-IQ at Ketone.com/BENG. LeelaQ: Not only do LeelaQ’s products neutralize EMFs, increase ATP production, optimize HRV, and improve blood flow, but they've been third-party proven to do so in placebo-controlled double-blind studies. Visit leelaq.com/ben and use code BEN10 for 10% off. Jaspr: Breathe air so clean you can smell the difference with the Jaspr commercial-grade air purifier. Visit Jaspr.co/ben and use code BEN for 10% off. RoXiva: Try out this world-class multisensory RX1 lamp, featuring meticulously crafted light and sound journeys that guide you effortlessly and reliably into new and expanded states of awareness. Get yours now by going to roXiva.com/ben! Our Place: Upgrade to Our Place today and say goodbye to forever chemicals in your kitchen. Go to fromourplace.com and enter my code BEN at checkout to receive 10% off sitewide.See omnystudio.com/listener for privacy information.

Dr. Ebony Hoskins and Dr. Andreas Obermair discuss the surgical management of gynecologic cancers, including the role of minimally invasive surgery, approaches in fertility preservation, and the nuances of surgical debulking. TRANSCRIPT Dr. Ebony Hoskins: Hello and welcome to the ASCO Daily News Podcast, I'm Dr. Ebony Hoskins. I'm a gynecologic oncologist at MedStar Washington Hospital Center in Washington, DC, and your guest host of the ASCO Daily News Podcast. Today we'll be discussing the surgical management of gynecologic cancer, including the role of minimally invasive surgery (MIS), approaches in fertility preservation, and the nuances of surgical debulking, timing, and its impact on outcomes. I am delighted to welcome Dr. Andreas Obermair for today's discussion. Dr. Obermair is an internationally renowned gynecologic oncologist, a professor of gynecologic oncology at the University of Queensland, and the head of the Queensland Center for Gynecologic Cancer Research. Our full disclosures are available in the transcript of this episode. Dr. Obermair, it's great speaking with you today. Dr. Andreas Obermair: Thank you so much for inviting me to this podcast. Dr. Ebony Hoskins: I am very excited.  I looked at your paper and I thought, gosh, is everything surgical? This is everything that I deal with daily in terms of cancer in counseling patients. What prompted this review regarding GYN cancer management? Dr. Andreas Obermair: Yes, our article was published in the ASCO Educational Book; it is volume 44 in 2024. And this article covers some key aspects of targeted precision surgical management principles in endometrial cancer, cervical cancer, and ovarian cancer. While surgery is considered the cornerstone of gynecologic cancer treatment, sometimes research doesn't necessarily reflect that. And so I think ASCO asked us to; so it was not just me, there was a team of colleagues from different parts of the United States and Australia to reflect on surgical aspects of gynecologic cancer care and I feel super passionate about that because I do believe that surgery has a lot to offer. Surgical interventions need to be defined and overall, I see the research that I'm doing as part of my daily job to go towards precision surgery. And I think that is, well, that is something that I'm increasingly passionate for. Dr. Ebony Hoskins: Well, I think we should get into it. One thing that comes to mind is the innovation of minimally invasive surgery in endometrial cancer. I always reflect on when I started my fellowship, I guess it's been about 15 years ago, all of our endometrial cancer patients had a midline vertical incision, increased risk of abscess, infections and a long hospital stay. Do you mind commenting on how you see management of endometrial cancer today? Dr. Andreas Obermair: Thank you very much for giving the historical perspective because the generation of gynecologic oncologists today, they may not even know what we dealt with, what problems we had to solve. So like you, when I was a fellow in gynecologic oncology, we did midline or lower crosswise incisions, the length of stay was, five days, seven days, but we had patients in hospital because of complications for 28 days. We took them back to the operating theaters because those are patients with a BMI of 40 plus, 45, 50 and so forth. So we really needed to solve problems. And then I was exposed to a mentor who taught minimal invasive surgery. And in Australia he was one of the first ones who embarked on that. And I can remember, I was mesmerized by this operation, like not only how logical this procedure was, but also we did rounds afterwards. And I saw these women after surgery and I saw them sitting upright, lipstick on, having had a full meal at the end of the day. And I thought, wow, this is the most rewarding experience that I have to round these patients after surgery. And so I was thinking, how could I help to establish this operation as standard? Like a standard that other people would accept this is better. And so I thought we needed to do a trial on this. And then it took a long time. It took a long time to get the support for the [LACE - Laparoscopic Approach to Cancer of the Endometrium] trial. And in this context, I just also wanted to remind us all that there were concerns about minimal invasive surgery in endometrial cancer at the time. So for example, one of the concerns was when I submitted my grant funding applications, people said, “Well, even if we fund you, wouldn't be able to do this trial because there are actually no surgeons who actually do minimally invasive surgery.” And at the time, for example, in Australia, there were maybe five people, a handful of people who were able to do this operation, right? This was about 20 years ago. The other concern people had was they were saying, could minimally invasive surgery for endometrial cancer, could that cause port side metastasis because there were case reports. So there were a lot of things that we didn't know anyway. We did this trial and I'm super happy we did this trial. We started in 2005, and it took five years to enroll. At the same time, GOG LAP2 was ramping up and the LACE trial and GOG LAP2 then got published and provided the foundations for minimally invasive surgery in endometrial cancer. I'm super happy that we have randomized data about that because now when we go back and now when people have concerns about this, should we do minimally invasive surgery in P53 mutant tumors, I'm saying, well, we actually have data on that. We could go back, we could actually do more research on that if we wanted to, but our treatment recommendations are standing on solid feet. Dr. Ebony Hoskins: Well, my patients are thankful. I see patients all the time and they have high risk and morbidly obese, lots of medical issues and actually I send them home most the same day. And I think, you know, I'm very appreciative of that research, because we obviously practice evidence-based and it's certainly a game changer. Let's go along the lines of MIS and cervical cancer. And this is going back to the LACC [Laparoscopic Approach to Cervical Cancer] trial.  I remember, again, one of these early adopters of use of robotic surgery and laparoscopic surgery for radical hysterectomy and thought it was so cool. You know, we can see all the anatomy well and then have the data to show that we actually had a decreased survival. And I even see that most recent updated data just showing it still continued. Can you talk a little bit about why you think there is a difference? I know there's ongoing trials, but still interested in kind of why do you think there's a survival difference? Dr. Andreas Obermair:  So Ebony, I hope you don't mind me going back a step. So the LACC study was developed from the LACE trial. So we thought we wanted to reproduce the LACE data/LAP2 data. We wanted to reproduce that in cervix cancer. And people were saying, why do you do that? Like, why would that be different in any way? We recognize that minimally invasive radical hysterectomy is not a standard. We're not going to enroll patients in a randomized trial where we open and do a laparotomy on half the patients. So I think the lesson that really needs to be learned here is that any surgical intervention that we do, we should put on good evidence footing because otherwise we're really running the risk of jeopardizing patients' outcomes. So, that was number one and LACC started two years after LACE started. So LACC started in 2007, and I just wanted to acknowledge the LACC principal investigator, Dr. Pedro Ramirez, who at the time worked at MD Anderson. And we incidentally realized that we had a common interest. The findings came totally unexpected and came as an utter shock to both of us. We did not expect this. We expected to see very similar disease-free and overall survival data as we saw in the endometrial cancer cohort. Now LACC was not designed to check why there was a difference in disease-free survival. So this is very important to understand. We did not expect it. Like, so there was no point checking why that is the case. My personal idea, and I think it is fair enough if we share personal ideas, and this is not even a hypothesis I want to say, this is just a personal idea is that in endometrial cancer, we're dealing with a tumor where most of the time the cancer is surrounded by a myometrial shell. And most of the time the cancer would not get into outside contact with the peritoneal cavity. Whereas in cervix cancer, this is very different because in cervix cancer, we need to manipulate the cervix and the tumor is right at the outside there. So I personally don't use a uterine manipulator. I believe in the United States, uterine manipulators are used all the time. My experience is not in this area, so I can't comment on that. But I would think that the manipulation of the cervix and the contact of the cervix to the free peritoneal cavity could be one of the reasons. But again, this is simply a personal opinion. Dr. Ebony Hoskins: Well, I appreciate it. Dr. Andreas Obermair: Ebony at the end of the day, right, medicine is empirical science, and empirical science means that we just make observations, we make observations, we measure them, and we pass them on. And we made an observation. And, and while we're saying that, and yes, you're absolutely right, the final [LACC] reports were published in JCO recently. And I'm very grateful to the JCO editorial team that they accepted the paper, and they communicated the results because this is obviously very important. At the same time, I would like to say that there are now three or four RCTs that challenge the LACC data. These RCTs are ongoing, and a lot of people will be looking forward to having these results available. Dr. Ebony Hoskins: Very good. In early-stage cervical cancer, the SHAPE trial looked at simple versus radical hysterectomy in low-risk cervical cancer patients. And as well all know, simple hysterectomy was not inferior to radical hysterectomy with respect to the pelvic recurrence rate and any complications related to surgery such as urinary incontinence and retention. My question for you is have you changed your practice in early-stage cervical cancer, say a patient with stage 1B1 adenocarcinoma with a positive margin on conization, would you still offer this patient a radical hysterectomy or would you consider a simple hysterectomy? Dr. Andreas Obermair:  I think this is a very important topic, right? Because I think the challenge of SHAPE is to understand the inclusion criteria. That's the main challenge. And most people simplify it to 2 cm, which is one of the inclusion criteria but there are two others and that includes the depth of invasion. Dr. Marie Plante has been very clear. Marie Plante is the first author of the SHAPE trial that's been published in the New England Journal of Medicine only recently and Marie has been very clear upfront that we need to consider all three inclusion criteria and only then the inclusion criteria of SHAPE apply. So at the end of the day, I think what the SHAPE trial is telling us that small tumors that would strictly fulfill the criteria of a 1B or 1B1 cancer of the cervix can be considered for a standard type 1 or PIVA type 1 or whatever classification we're trying to use will be eligible. And that makes a lot of sense. I personally not only look at the size, I also look at the location of the tumor. I would be very keen that I avoid going through tumor tissue because for example, if you have a tumor that is, you know, located very much in one corner of the cervix and then you do a standard hysterectomy and then you have a positive tumor margin that would be obviously, most people would agree it would be an unwanted outcome. So I'd be very keen checking the location, the size of the tumor, the depths of invasion and maybe then if the tumor for example is on one side of the cervix you can do a standard approach on the contralateral side but maybe do a little bit more of a margin, a parametrial margin on the other side. Or if a tumor is maybe on the posterior cervical lip, then you don't need to worry so much about the anterior cervical margin, maybe take the rectum down and maybe try to get a little bit of a vaginal margin and the margin on the uterus saccals. Just really to make sure that you do have margins because typically if we get it right, survival outcomes of clinical stage 1 early cervix cancer 1B1 1B 2 are actually really good. It is a very important thing that we get the treatment right. In my practice, I use a software to record my treatment outcomes and my margins. And I would encourage all colleagues to be cognizant and to be responsible and accountable to introduce accountable clinical practice, to check on the margins and check on the number on the percentage of patients who require postoperative radiation treatment or chemo radiation. Dr. Ebony Hoskins: Very good. I have so many questions for you. I don't know the statistics in Australia, but here, there's increased rising of endometrial cancer and certainly we're seeing it in younger women. And fertility always comes up in terms of kind of what to do. And I look at the guidelines and, see if I can help some of the women if they have early-stage endometrial cancer. Your thoughts on what your practice is on use of someone who may meet criteria, if you will. The criteria I use is grade 1 endometrioid adenocarcinoma. No myometria invasion. I try to get MRI'd and make sure that there's no disease outside the endometrium. And then if they make criteria, I typically would do an IUD. Can you tell me what your practice is and where you've had success? Dr. Andreas Obermair: So, we initiated the feMMe clinical trial that was published in 2021 and it was presented in a Plenary at one of the SGO meetings. I think it was in 2021, and we've shown complete pathological response rates after levonorgestrel intrauterine device treatment. And so in brief, we enrolled patients with endometrial hyperplasia with atypia, but also patients with grade 1 endometrial adenocarcinoma. Patients with endometrial hyperplasia with atypia had, in our series, had an 85 % chance of developing a complete pathological response. And that was defined as the complete absence of any atypia or cancer. So endometrial hyperplasia with atypia responded in about 85%. In endometrial cancer, it was about half, it was about 45, 50%. In my clinical practice, like as you, I see patients, you know, five days a week. So I'm looking after many patients who are now five years down from conservative treatment of endometrial cancer. There are a lot of young women who want to get pregnant, and we had babies, and we celebrate the babies obviously because as gynecologist obstetricians it couldn't get better than that, right, if our cancer patients have babies afterwards. But we're also treating women who are really unfit for surgery and who are frail and where a laparoscopic hysterectomy would be unsafe. So this phase is concluded, and I think that was very successful. At least we're looking to validate our data. So we're having collaborations, we're having collaborations in the United States and outside the United States to validate these data. And the next phase is obviously to identify predictive factors, to identify predictors of response. Because as you can imagine, there is no point treating patients with a levonorgestrel intrauterine joint device where we know in advance that she's not going to respond. So this is a very, very fascinating story and we got our first set of data already, but now we just really need to validate this data. And then once the validation is done, my unit is keen to do a prospective validation trial. And that also needs to involve international collaborators. Dr. Ebony Hoskins: Very good. Moving on to ovarian cancer, we see patients with ovarian cancer with, say, at least stage 3C or higher who started neoadjuvant chemotherapy. Now, some of these patients are hearing different things from their medical oncologist versus their gynecologic oncologist regarding the number of cycles of neoadjuvant chemotherapy after getting diagnosed with ovarian cancer. I know that this can be confusing for our patients coming from a medical oncologist versus a gynecologic oncologist. What do you say to a patient who is asking about the ideal number of chemotherapy cycles prior to surgery? Dr. Andreas Obermair: So this is obviously a very, very important topic to talk about. We won't be able to provide a simple off the shelf answer for that, but I think data are emerging.  The ASCO guidelines should also be worthwhile considering because there are actually new ASCO Guidelines [on neoadjuvant chemotherapy for newly diagnosed, advanced ovarian cancer] that just came out a few weeks ago and they would suggest that we should be aiming for R0 in surgery. If we can maybe take that as the pivot point and then go back and say, okay, so what do need to do to get the patient to zero?  I'm not an ovarian cancer researcher; I'm obviously a practicing gynecologic oncologist. I think about things a lot and things like that. In my practice, I would want a patient to develop a response after neoadjuvant chemotherapy. So, if a patient doesn't have a response after two or three cycles, then I don't see the point for me to offer her an operation. In my circle with the medical oncologists that I work with, I have a very, very good understanding. So, they send the patient to me, I take them to the theater. I take a good chunk of tissue from the peritoneum. We have a histopathologic diagnosis, we have a genomic diagnosis, they go home the same day. So obviously there is no hospital stay involved with that. They can start the chemotherapy after a few days. There is no hold up because the chances of surgical complication in a setting like this is very, very low. So I use laparoscopy to determine whether the patient responds or not. And for many of my patients, it seems to work. It's obviously a bit of an effort and it takes operating time. But I think I'm increasing my chances to make the right decision. So, coming back to your question about whether we should give three or six cycles, I think the current recommendations are three cycles pending the patient's response to neoadjuvant chemotherapy because my aim is to get a patient to R0 or at least minimal residual disease. Surgery is really, in this case, I think surgery is the adjunct to systemic treatment. Dr. Ebony Hoskins: Definitely. I think you make a great point, and I think the guideline just came out, like you mentioned, regarding neoadjuvant. And I think the biggest thing that we need to come across is the involvement of a gynecologic oncologist in patients with ovarian cancer. And we know that that survival increases with that involvement. And I think the involvement is the surgery, right? So, maybe we've gotten away from the primary tumor debulking and now using more neoadjuvant, but surgery is still needed. And so, I definitely want to have a take home that GYN oncology is involved in the care of these patients upfront. Dr. Andreas Obermair: I totally support that. This is a very important statement. So when I'm saying surgery is the adjunct to medical treatment, I don't mean that surgery is not important. Surgery is very important. And the timing is important. And that means that the surgeons and the med oncs need to be pulling on the same string. The med oncs just want to get the cytotoxic into the patients, but that's not the point, right? We want to get the cytotoxic into the patients at the right time because if we are working under this precision surgery, precision treatment mantra, it's not only important what we do, but also doing it at the right time. And ideally, I I would like to give surgery after three cycles of neoadjuvant chemotherapy, if that makes sense. But sometimes for me as a surgeon, I talk to my med onc colleagues and I say, “Look, she doesn't have a good enough response to her treatment and I want her to receive six cycles and then we re-evaluate or change medical treatment,” because that's an alternative that we can swap out drugs and treat upfront with a different drug and then sometimes they do respond. Dr. Ebony Hoskins:  I have maybe one more topic. In the area I'm in, in the Washington D.C. area, we see lots of endometrial cancer and they're not grade 1, right? They're high-risk endometrial cancer and advanced. So a number of patients with stage 3 disease, some just kind of based off staging and then some who come in with disease based off of the CT scan, sometimes omental caking, ascites. And the real question is we have extrapolated the use of neoadjuvant chemotherapy to endometrial cancer. It's similar, but not the same. So my question is in an advanced endometrial cancer, do you think there's still a role, when I say advanced, I mean, maybe stage 4, a role for surgery? Dr. Andreas Obermair: Most definitely. But the question is when do you want to give this surgery? Similar to ovarian cancer, in my experience, I want to get to R0. What am I trying to achieve here? So, I reckon we should do a trial on this. And I reckon we have, as you say, the number of patients in this setting is increasing, we could do a trial. I think if we collaborate, we would have enough patients to do a proper trial. Obviously, we would start maybe with a feasibility trial and things like that. But I reckon a trial would be needed in this setting because I find that the incidence that you described, that other people would come across, they're becoming more and more common. I totally agree with you, and we have very little data on that. Dr. Ebony Hoskins: Very little and we're doing what we can. Dr. Obermair, thank you for sharing your fantastic insights with us today on the ASCO Daily News Podcast and for all the work you do to advance care for patients with gynecologic cancer. Dr. Andreas Obermair: Thank you, Dr. Hoskins, for hosting this and it's been an absolute pleasure speaking with you today. Dr. Ebony Hoskins: Definitely a pleasure and thank you to our listeners for your time today. Again, Dr. Obermair's article is titled, “Controversies in the Surgical Management of Gynecologic Cancer: Balancing the Decision to Operate or Hesitate,” and was published in the 2024 ASCO Educational Book. And you'll find a link to the article in the transcript of this episode. Finally, if you value the insights that you hear on the ASCO Daily News Podcast, please take a moment to rate, review and subscribe wherever you get your podcasts. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity or therapy should not be construed as an ASCO endorsement. Find out more about today's speakers: Dr. Ebony Hoskins @drebonyhoskins Dr. Andreas Obermair @andreasobermair Follow ASCO on social media:       @ASCO on Twitter       ASCO on Bluesky   ASCO on Facebook       ASCO on LinkedIn       Disclosures:   Dr. Ebony Hoskins: No relationships to disclose. Dr. Andreas Obermair: Leadership: SurgicalPerformance Pty Ltd. Stock and Ownership Interests: SurgicalPerformance Pty Ltd. Honoraria: Baxter Healthcare Consulting or Advisory Role: Stryker/Novadaq Patents, Royalties, and Other Intellectual Property: Shares in SurgicalPerformance Pty Ltd. Travel, Accommodation, Expenses: Stryker    

For decades, we've been told that our DNA is a fixed blueprint—an unchangeable code that dictates our health and lifespan. But what if that's only half the story? Sharon Hausman-Cohen, a physician, researcher, and genomics expert at IntellxxDNA, joins Dave to reveal the cutting-edge science of genetic optimization—how understanding your DNA can unlock longer life, better brain function, and even protection from chronic disease. Forget the old-school genetic reports that left you with useless percentages. The new frontier of precision genomics goes beyond risk factors to actionable insights, showing you exactly how to turn on your body's most powerful longevity genes and turn off the pathways driving inflammation, cognitive decline, and disease. What You'll Learn in This Episode: • Why genetics alone don't determine your future—and how to use epigenetics to control your health • The truth about MTHFR, APOE4, and other “bad” genes—are they actually harming you? • How genetic reports can predict and eliminate brain fog, fatigue, and pain • The hidden genetic reasons behind ADHD, depression, and anxiety—and how to fix them • Why some people age faster—and the one longevity gene that determines your biological age • Cutting-edge breakthroughs in DNA-based biohacking—is it possible to edit your genes for peak performance? This is the future of personalized medicine. By understanding your own genetic blueprint, you can stop guessing and start making the precise changes that will optimize your energy, brainpower, and lifespan! ** Visit IntellxxDNA at https://intellxxdna.com/asprey/ When you go to the website to find a clinician please select “human upgrade/longevity” as the type of consult to get specialized biohacking clinicians! ** SPONSORS -Timeline | Head to https://www.timeline.com/dave to get 10% off your first order. -Leela Quantum Tech | Head to https://leelaq.com/DAVE for 10% off. Resources: • Dave Asprey's New Book - Heavily Meditated: https://daveasprey.com/heavily-meditated/ • IntellxxDNA Website: https://intellxxdna.com/asprey/ • 2025 Biohacking Conference: https://biohackingconference.com/2025 • Danger Coffee: https://dangercoffee.com • Dave Asprey's Website: https://daveasprey.com • Dave Asprey's Linktree: https://linktr.ee/daveasprey • Upgrade Collective – Join The Human Upgrade Podcast Live: https://www.ourupgradecollective.com • Own an Upgrade Labs: https://ownanupgradelabs.com • Upgrade Labs: https://upgradelabs.com • 40 Years of Zen – Neurofeedback Training for Advanced Cognitive Enhancement: https://40yearsofzen.com Timestamps: • 00:00 – Intro • 02:00 – The Role of Genetics in Longevity • 03:37 – Gene Variants & Cognitive Health • 05:58 – Epigenetics vs. Genetics • 08:21 – Genomics & Pain Management • 09:26 – Breakthroughs in Genetic Research • 12:33 – The Future of Genomic Medicine • 14:27 – How to Use Genomic Reports • 38:25 – Mitochondria & Longevity • 42:40 – BH4 & Mental Health • 43:42 – Folinic Acid & Brain Function • 44:37 – Genomics & Autism • 46:06 – Personalized Medicine • 56:00 – APOE4 & Alzheimer's Risk • 59:44 – Genetics & Heart Health • 01:04:54 – The Future of Precision Medicine • 01:20:23 – Conclusion & Next Steps See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

More women than men have died from cardiovascular disease in modern times, yet we continue to believe it is primarily a problem for men. Your cardiometabolic health determines how you are able to show up in the world and can be a key indicator of your health going forward. This is why it is so important to know which signs to pay attention to so that you can pivot as your body pivots. Protecting Your Aliveness with Dr. Sara Gottfried Sara Gottfried, MD is a board-certified physician, researcher, and educator. She graduated from Harvard Medical School and MIT, and completed residency at UCSF. Dr. Gottfried is a global keynote speaker and the author of four New York Times bestselling books about trauma, hormones, and physical and mental health—including her latest titled WOMEN, FOOD, AND HORMONES. Dr. G has also completed a 2-year fellowship in Advanced Cardiometabolic Health at the Metabolic Medical Institute, and she is Clinical Assistant Professor in Dept. of Integrative Medicine and Nutritional Sciences at Thomas Jefferson University, and Director of Precision Medicine at the Marcus Institute of Integrative Health. Her focus is diet, nutrition, and peak performance. In This Episode Differentiating the role of glucose when it comes to your vascular health (12:32) At what age you should start to look at your cardio-metabolic health with a fine tooth comb (20:06) How to work to change the system and protect women at risk for heart attack (24:33) Understanding the advanced cardiovascular markers and how to identify them (34:51) Tips for adjusting your diet if you are dealing with insulin resistance and improving your metabolic flexibility (46:08) Mentioned In This Episode Women Food and Hormones by Dr. Sara Gottfried Related Resources Check out the full show notes page Keep up with everything Dr. Mariza Follow Dr. Mariza on Facebook | Instagram | Twitter | YouTube Related Episodes #314: Why So Many Women Struggle with Stubborn Weight and the Benefits of Keto for Hormone Health with Dr. Sara Gottfried #426: 10 Most Common Reasons Your Glucose Levels are Rising Up

There hasn't been much data collected on the vaginal microbiome - until now. Priyanka Jain is the Co-Founder & CEO of Evvy, which she started to unlock precision medicine for women by discovering and leveraging overlooked female biomarkers, starting with the vaginal microbiome. Hear the importance of the vaginal microbiome, how Evvy's vaginal microbiome test works, their business model & revenue streams, how Evvy is bridging the gender gap in medical research & data, and her aspirations to become the leading women's health database. Tune in to this episode to unlock precision medicine for women!   Learn more: Priyanka Jain Evvy Evvy LinkedIn   Today's Hot Flash and other stats from: International Microbiota Observatory

In the first episode of A Deep Dive into HRD Testing in Ovarian Cancer, a three-part podcast series sponsored by AstraZeneca, we're speaking with Dr. Kathleen Moore about HRD testing in ovarian cancer and its clinical significance in helping aid precision medicine approaches.   Dr. Kathleen Moore is a Professor of Gynecologic Oncology at the University of Oklahoma Health Sciences Center, Associate Director of Clinical Research and Director of the Oklahoma TSET Phase I Program at the Stephenson Cancer Center. A graduate of the University of Washington School of Medicine, WA, Dr. Moore completed her residency in gynecology at the University Health Center of Pittsburgh in Pittsburgh, PA and completed a fellowship in gynecologic oncology at the University of Oklahoma College of Medicine in Oklahoma City, OK. She is board certified in obstetrics and gynecology as well as gynecologic oncology and hospice and palliative care.   For more information, visit: https://www.azprecisionmed.com/tumor-type/ovarian-cancer/hrd-testing.html For patient resources, please visit TestForHRD.com.   This podcast does not necessarily reflect the opinions of AstraZeneca and are the spokeperson's opinions and experience.